ISR interim report H1 2022: Full charges ahead of the curve

Research Note

2022-09-05

07:30

Redeye comments on ISR’s interim half-year 2022 report. It has been an eventful first-half year and intense work for ISR in terms of the clinical development of the company’s HIV drug candidate ISR48 and their nasally inhaled dry powder vaccine against SARS-CoV-2 ISR52, laying the fundaments for commercialization. However, Redeye notes that ISR is in a precarious financial situation, and the next coming months will be decisive for ISR’s future direction.

EL

JU

Ethel Luvall

Johan Unnerus

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.